Profile

Quris-AI is committed to revolutionizing drug development by accurately predicting human drug responses, reducing the high failure rates of clinical trials, and minimizing the need for animal testing. Their mission is to accelerate the discovery of safe, effective treatments through the integration of advanced AI, machine learning, and patient-on-chip technology, ultimately making healthcare safer, faster, and more personalized.

Visit www.quris.ai

Key Products

Bio-AI Clinical Prediction Platform:

A groundbreaking platform that leverages AI and patient-on-chip technology to predict human drug safety and efficacy with unprecedented accuracy, reducing reliance on animal testing and improving clinical trial success rates.

Patient-on-Chip Technology:

This miniaturized system simulates human organs and physiological responses, enabling more accurate drug testing and safety prediction while reducing development time and costs.

Key Executives

Dr. Isaac Bentwich , CEO and Founder

A visionary leader with extensive experience in AI-driven healthcare innovation. Dr. Bentwich has pioneered Quris-AI’s Bio-AI platform to revolutionize drug development. He is an advocate for ethical, efficient drug discovery and is dedicated to transforming the industry with AI and patient-on-chip technology.

Dr. Amir Bein, Shahar Harel, VP Biology & VP AI

Dr. Bein leads the biology scientific initiatives at Quris-AI and the development of the patient-on-chip platform, and brings pioneering expertise in bioengineering and translational science. Shahar Harel brings cutting-edge experience in using Generative AI in drug design and other domains. Their combined skills are crucial in advancing Quris-AI’s mission to make drug development more predictive and cost-effective.

Prof. Robert S. Langer, Scientific Advisor

Co-founder of Moderna and former Chairman of the FDA Science Board, Prof. Langer brings unparalleled expertise in biotechnology and drug development. He plays a key advisory role in guiding Quris-AI’s scientific strategy.

Customer Insights

“Based on the results of our initial collaboration, we are looking forward to exploring how its BioAI platform can advance our drug development and testing programs and working towards an AI-enabled IND process that reduces the reliance on animal testing. If we could better focus on developing safe and effective drug candidates, we would be able to reduce significant time and cost investments.” -Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck KGaA, Darmstadt, Germany.

“Ground-breaking Platform” -Frost & Sullivan report, 2023

“Unique. Synergistic with other AI players” -Deloitte

Competitors

• Recursion


• Isomorphic


• Emulate.

Investors

With an impressive total funding of over $50 million raised so far, featuring a significant $37 million seed round led by Softbank, Quris-AI has proven to be a promising Israeli startup. With a deep portfolio, Quris holds 29 patents (both approved and pending) related to Bio-AI, nano sensing, and drug substances. Currently, Quris is engaged in a collaboration with Merck KGaA, a top-tier pharma company, and has several other tier#1 pharma collaboration discussions in progress.

Corporate Responsibility

At Quris-AI, they are committed to reshaping the future of healthcare by prioritizing ethical practices in drug development. Their efforts to reduce reliance on animal testing and advance personalized medicine reflect their dedication to sustainability and corporate responsibility. They actively support diversity, equity, and inclusion (DE&I) within their teams and ensure that their innovations benefit a broad range of communities worldwide.